254 related articles for article (PubMed ID: 12698311)
1. Under-prescribing of cardiovascular therapies for diabetes in primary care.
Bennett KE; Williams D; Feely J
Eur J Clin Pharmacol; 2003 Apr; 58(12):835-41. PubMed ID: 12698311
[TBL] [Abstract][Full Text] [Related]
2. Secondary prevention therapies for coronary heart disease in patients with type 2 diabetes: an audit.
Sharma KK; Guptha S; Gupta R
J Assoc Physicians India; 2012 Apr; 60():28-30. PubMed ID: 23029739
[TBL] [Abstract][Full Text] [Related]
3. Inequalities in prescribing of secondary preventative therapies for ischaemic heart disease in Ireland.
Bennett KE; Williams D; Feely J
Ir Med J; 2002 Jun; 95(6):169-72. PubMed ID: 12171263
[TBL] [Abstract][Full Text] [Related]
4. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis.
Hippisley-Cox J; Coupland C
BMJ; 2005 May; 330(7499):1059-63. PubMed ID: 15879390
[TBL] [Abstract][Full Text] [Related]
5. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care.
Williams D; Bennett K; Feely J
Br J Clin Pharmacol; 2003 Jun; 55(6):604-8. PubMed ID: 12814456
[TBL] [Abstract][Full Text] [Related]
6. Changes in prevalence of and prescribing for ischaemic heart disease in Ireland 1990-2002.
Bennett K; Johnson H; Dack P; Shelley E; Feely J
Ir J Med Sci; 2005; 174(3):4-8. PubMed ID: 16285330
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery.
Barry AR; Koshman SL; Norris CM; Ross DB; Pearson GJ
Pharmacotherapy; 2014 May; 34(5):464-72. PubMed ID: 24877186
[TBL] [Abstract][Full Text] [Related]
8. Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study.
Fadini GP; Frison V; Simioni N; Lapolla A; Gatti A; Bossi AC; Del Buono A; Fornengo P; Gottardo L; Laudato M; Perseghin G; Bonora E; Avogaro A
J Am Heart Assoc; 2019 Jul; 8(14):e012244. PubMed ID: 31269877
[TBL] [Abstract][Full Text] [Related]
9. Prescription of statins: cost implications of evidence-based treatment applied to a health authority population.
Bradshaw N; Walker R
J Clin Pharm Ther; 1997; 22(5-6):379-89. PubMed ID: 19160723
[TBL] [Abstract][Full Text] [Related]
10. Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial.
Pagidipati NJ; Nelson AJ; Kaltenbach LA; Leyva M; McGuire DK; Pop-Busui R; Cavender MA; Aroda VR; Magwire ML; Richardson CR; Lingvay I; Kirk JK; Al-Khalidi HR; Webb L; Gaynor T; Pak J; Senyucel C; Lopes RD; Green JB; Granger CB;
JAMA; 2023 Apr; 329(15):1261-1270. PubMed ID: 36877177
[TBL] [Abstract][Full Text] [Related]
11. Regional variation in the prescribing for diabetes and use of secondary preventative therapies in Ireland.
Usher C; Bennett K; Feely J
Pharmacoepidemiol Drug Saf; 2005 Aug; 14(8):537-44. PubMed ID: 15818637
[TBL] [Abstract][Full Text] [Related]
12. Enhancing prescribing of guideline-recommended medications for ischaemic heart diseases: a systematic review and meta-analysis of interventions targeted at healthcare professionals.
Nguyen T; Nguyen HQ; Widyakusuma NN; Nguyen TH; Pham TT; Taxis K
BMJ Open; 2018 Jan; 8(1):e018271. PubMed ID: 29326185
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological treatment after acute myocardial infarction from 2001 to 2006: a survey in Italian primary care.
Filippi A; D'Ambrosio G; Giustini SE; Pecchioli S; Mazzaglia G; Cricelli C
J Cardiovasc Med (Hagerstown); 2009 Sep; 10(9):714-8. PubMed ID: 19465867
[TBL] [Abstract][Full Text] [Related]
14. Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India.
Sharma KK; Gupta R; Agrawal A; Roy S; Kasliwal A; Bana A; Tongia RK; Deedwania PC
Vasc Health Risk Manag; 2009; 5():1007-14. PubMed ID: 19997570
[TBL] [Abstract][Full Text] [Related]
15. Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted follow-up.
Turley AJ; Roberts AP; Morley R; Thornley AR; Owens WA; de Belder MA
Interact Cardiovasc Thorac Surg; 2008 Apr; 7(2):231-4. PubMed ID: 18234766
[TBL] [Abstract][Full Text] [Related]
16. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.
Naderi SH; Bestwick JP; Wald DS
Am J Med; 2012 Sep; 125(9):882-7.e1. PubMed ID: 22748400
[TBL] [Abstract][Full Text] [Related]
17. Optimizing prevention and guideline-concordant care in Montenegro.
Knežević B; Musić L; Batrićević G; Bošković A; Bulatović N; Nenezić A; Vujović J; Kalezić M
Int J Cardiol; 2016 Aug; 217 Suppl():S32-6. PubMed ID: 27381861
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction.
Austin PC; Tu JV; Ko DT; Alter DA
CMAJ; 2008 Oct; 179(9):901-8. PubMed ID: 18936455
[TBL] [Abstract][Full Text] [Related]
19. Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry.
Maddox TM; Ho PM; Roe M; Dai D; Tsai TT; Rumsfeld JS
Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):632-41. PubMed ID: 20923997
[TBL] [Abstract][Full Text] [Related]
20. The use of nitrates, calcium channel blockers and ACE inhibitors in primary care in the Northern Region: a pharmacoepidemiological study.
Roberts SJ; Bateman DN
Br J Clin Pharmacol; 1994 Dec; 38(6):489-97. PubMed ID: 7888286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
